Skip to main content
Erschienen in: BMC Cancer 1/2019

Open Access 01.12.2019 | Correction

Correction to: Cervical and breast cancer screening uptake among women with serious mental illness: a data linkage study

verfasst von: Charlotte Woodhead, Ruth Cunningham, Mark Ashworth, Elizabeth Barley, Robert J. Stewart, Max J. Henderson

Erschienen in: BMC Cancer | Ausgabe 1/2019

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
Charlotte Woodhead and Ruth Cunningham contributed equally to this work.
The original article can be found online at https://​doi.​org/​10.​1186/​s12885-016-2842-8
Correction to: BMC Cancer (2016) 16:819
Following publication of the original article [1], the authors notified us of an error in the reported percentages in Table 3.
Table 3
Associations between serious mental illness (SMI) status and recent receipt of breast and/or cervical screening overall and by SMI characteristic sub-group
 
Mammography eligible population (N=26,010)
Cervical smear eligible population (N=107,947)
Recorded mammography in last 3 years n (%)
Unadjusted OR (95% CI)
Adjusted for socio-demographics ORa (95% CI)
Additionally adjusted for consultation rate ORb (95% CI)
Recorded cervical smear in last 3/5 yrs n (%)
Unadjusted OR (95% CI)
Adjusted for socio-demographics ORa (95% CI)
Additionally adjusted for consultation rate ORb (95% CI)
Non-SMI
14205 (56.0)
1.00
1.00
1.00
67823 (63.7)
1.00
1.00
1.00
SMI overall
305 (48.8)
0.72 (0.61 - 0.86)***
0.69 (0.57 - 0.84)***
0.60 (0.49 - 0.73)***
848 (60.9)
1.16 (0.99 - 1.35)
0.72 (0.60 - 0.85)***
0.35 (0.29 - 0.42)***
SMI by diagnosis
 Schizophrenia
136 (47.9)
0.64 (0.50 - 0.82)***
0.59 (0.45 - 0.78)***
0.52 (0.40 - 0.69)***
270 (57.3)
0.95 (0.74 - 1.22)
0.48 (0.36 - 0.63)***
0.24 (0.18 - 0.32)***
 Bipolar affective disorder
67 (50.4)
0.85 (0.58 - 1.26)
0.89 (0.59 - 1.35)
0.72 (0.47 - 1.10)
231 (67.9)
1.94 (1.35 - 2.78)***
1.23 (0.84 - 1.80)
0.50 (0.33 - 0.74)**
 Other non-organic psychoses
34 (41.5)
0.54 (0.33 - 0.87)*
0.53 (0.31 - 0.90)*
0.47 (0.27 - 0.80)**
153 (56.7)
0.82 (0.60 - 1.13)
0.57 (0.40 - 0.80)**
0.33 (0.22 - 0.47)***
Depot injectable
 No
191 (53.4)
0.94 (0.74 - 1.20)
0.97 (0.75 - 1.26)
0.83 (0.64 - 1.09)
524 (63.1)
0.32 (1.08 - 1.62)**
0.82 (0.65 - 1.02)
0.36 (0.29 - 0.46)***
 Yes
80 (42.6)
0.50 (0.37 - 0.68)***
0.46 (0.33 - 0.64)***
0.39 (0.27 - 0.54)***
199 (58.5)
0.92 (0.69 - 1.22)
0.48 (0.35 - 0.66)***
0.26 (0.18 - 0.36)***
Any indicator of severity1
 No
168 (53.7)
1.00 (0.77 - 1.29)
0.91 (0.69 - 1.21)
0.79 (0.59 - 1.06)
411 (62.7)
1.32 (1.05 - 1.66)*
0.82 (0.63 - 1.06)
0.40 (0.31 - 0.53)***
 Yes
137 (43.9)
0.54 (0.43 - 0.69)***
0.54 (0.42 - 0.70)***
0.46 (0.36 - 0.61)***
437 (59.2)
1.04 (0.85 - 1.27)
0.65 (0.52 - 0.81)***
0.31 (0.25 - 0.40)***
Any indicator of risk2
 No
205 (51.4)
0.84 (0.67 - 1.05)
0.81 (0.63-1.03)
0.70 (0.55 - 0.90)**
535 (62.9)
1.31 (1.07 - 1.60)**
0.79 (0.63 - 1.00)*
0.38 (0.30 - 0.49)***
 Yes
100 (44.2)
0.56 (0.42 - 0.74)***
0.53 (0.39 - 0.73)***
0.46 (0.34 - 0.63)***
313 (57.6)
0.97 (0.77 - 1.23)
0.62 (0.48 - 0.80)***
0.31 (0.24 - 0.41)***
Eligible population includes non-linked non-SMI and linked SMI group
*p < 0.05, **p < 0.01, ***p < 0.001
1 Includes any of: ever had an inpatient stay, any record of being treated under the Mental Health Act, any record of difficulty managing their physical health, or any record of an Assertive Outreach/Crisis/A&E episode
2 Includes any of: recorded history of violence, recorded history of non-compliance, and any record of a forensic history
a Adjusted for age (continuous), ethnicity, and borough-level deprivation
b Additionally adjusted for mean annual number of primary consultations
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
download
DOWNLOAD
print
DRUCKEN
Metadaten
Titel
Correction to: Cervical and breast cancer screening uptake among women with serious mental illness: a data linkage study
verfasst von
Charlotte Woodhead
Ruth Cunningham
Mark Ashworth
Elizabeth Barley
Robert J. Stewart
Max J. Henderson
Publikationsdatum
01.12.2019
Verlag
BioMed Central
Erschienen in
BMC Cancer / Ausgabe 1/2019
Elektronische ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5357-2

Weitere Artikel der Ausgabe 1/2019

BMC Cancer 1/2019 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.